G protein-coupled receptor signaling complexity in neuronal tissue: Implications for novel therapeutics

Current Alzheimer Research

Volumn 4, Issue 1, 2007, Pages 3-19

  Maudsley, Stuart ^a,d   Martin, Bronwen ^a   Luttrell, Louis M ^b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

DOWN REGULATION; HUMAN; LIGAND BINDING; MEMBRANE TRANSPORT; MOLECULAR MODEL; NERVOUS TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NERVE TISSUE; NEURONS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 33847119788     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507779939850     Document Type: Review

References (187)

1. Hur EM and Kim KT. G protein-coupled receptor signaling and cross-talk: achieving rapidity and specificity. Cell Signal 14:397-405 (2002).
2. Takeda S, Kadowaki S, Haga T, Takaesu H and Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 520:97-101 (2002).
3. Brink CB, Harvey BH, Bodenstein J, Venter DP and Oliver DW. Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br J Clin Pharmacol 57:373-387 (2004).
4. Karlin A. On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. J Theor Biol 16:306-320 (1967).
5. Rodbell M, Birnbaumer L, Pohl SL and Krans HM. The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action. J Biol Chem 246: 1877-1882 (1971).
6. DeLean A, Stadel JM and Lefkowitz RJ. A ternary complex model explains the agonist specific binding properties of the adenylyl cyclase-coupled beta-adrenergic receptor. J Biol Chem 255: 7108-7117 (1980).
7. Cotecchia S, Exum S, Caron MG and Lefkowitz RJ. Regions of the α1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci U S A 87:2896-2900 (1990).
8. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG and Lefkowitz RJ. Constitutive activation of the α1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433 (1992).
9. Samama P, Pei G, Costa T, Cotecchia S and Lefkowitz RJ. Negative antagonists promote an inactive conformation of the β2-adrenergic receptor. Mol Pharmacol 45:390-394 (1994).
10. Lefkowitz RJ, Cotecchia S, Samama P and Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307 (1993).
11. Samama P, Cotecchia S, Costa T and Lefkowitz RJ. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636 (1993).
12. Kenakin T. Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16:188-192 (1995).
13. Yan B, Takahashi T, Johnson R and Spudich JL. Identification of signaling states of a sensory receptor by modulation of lifetimes of stimulus-induced conformations: the case of sensory rhodopsin II. Biochemistry 30: 10686-10682 (1991).
14. Farahbakhsh ZT, Hideg K and Hubbell WL. Photoactivated conformational changes in rhodopsin: a time-resolved spin label study. Science 262: 1416-1419 (1993).
15. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P and Clarke WP. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104 1(1998).
16. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170-175 (1993).
17. Meller E, Puza T, Diamond J, Lieu HD and Bohmaker K. Comparative effects of receptor inactivation, 17 β-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro. J Pharmacol Exp Ther 263:462-469 (1992).
18. Sagan S, Karoyan P, Chassaing G and Lavielle S. Further delineation of the two binding sites (R*(n)) associated with tachykinin neurokinin-1 receptors using [3-Prolinomethionine(11)]SP analogues. J Biol Chem 274:23770-23776 (1999).
19. Bonhaus DW, Chang LK, Kwan J and Martin GR. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287:884-888 (1998).
20. Krumins AM and Barber R. The stability of the agonist β2-adrenergic receptor-Gs complex: evidence for agonist-specific states. Mol Pharmacol 52:144-154 (1997).
21. Scaramellini C and Leff P. A three-state receptor model: predictions of multiple agonist pharmacology for the same receptor type. Ann N Y Acad Sci 861:97-103 (1998).
22. Seifert R, Gether U, Wenzel-Seifert K and Kobilka BK. Effects of guanine, inosine, and xanthine nucleotides on β(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. Mol Pharmacol 56:348-358 (1999).
23. Abadji V, Lucas-Lenard JM, Chin C and Kendall DA. Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J Neurochem 72:2032-2038 (1999).
24. Barroso S, Richard F, Nicolas-Etheve D, Kitabgi P and Labbe-Jullie C. Constitutive activation of the neurotensin receptor 1 by mutation of Phe(358) in Helix seven. Br J Pharmacol 135:997-1002 (2002).
25. Christopoulos A and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374 (2002).
26. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379 (2002).
27. Leff P, Scaramellini C, Law C and McKechnie K. A three-state receptor model of agonist action. Trends Pharmacol Sci 18:355-362 (1997).
28. Gether U, Lin S and Kobilka BK. Fluorescent labeling of purified β2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 270:28268-28275 (1995).
29. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J Biol Chem 276:24433-24436 (2001).
30. Evans PD, Robb S, Cheek TR, Reale V, Hannan FL, Swales LS, et al. Agonist-specific coupling of G-protein-coupled receptors to second-messenger systems. Prog Brain Res 106:259-268 (1995).
31. Downes GB and Gautam N. The G protein subunit gene families. Genomics 62:544-552 (1999).
32. Kleuss C, Scherubl H, Hescheler J, Schultz G and Wittig B. Different beta-subunits determine G-protein interaction with transmembrane receptors. Nature 358: 424-426 (1992).
33. Kleuss C, Scherubl H, Hescheler J, Schultz G and Wittig B. Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science 259: 832-834 (1993).
34. Paasche JD, Attramadal T, Sandberg C, Johansen HK and Attramadal H. Mechanisms of endothelin receptor subtype-specific targeting to distinct intracellular trafficking pathways. J Biol Chem 276:34041-34050 (2001).
35. Blank JL, Brattain KA and Exton JH. Activation of cytosolic phosphoinositide phospholipase C by G-protein beta gamma subunits. J Biol Chem 267:23069-23075 (1992).
36. Exton JH. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annu Rev Pharmacol Toxicol 36:481-509 (1996).
37. Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N and Knopf JL. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 65:1043-1051 (1991).
38. Schievella AR, Regier MK, Smith WL and Lin LL. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem 270:30749-30754 (1995).
39. Felder CC, Jose PA and Axelrod J. The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylyl cyclase. J Pharmacol Exp Ther 248:171-175 (1989).
40. Jones SB, Halenda SP and Bylund DB. Alpha 2-adrenergic receptor stimulation of phospholipase A2 and of adenylyl cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms. Mol Pharmacol 39:239-245 (1991).
41. Allgeier A, Laugwitz KL, Van-Sande J, Schultz G, and Dumont JE. Multiple G-protein coupling of the dog thyrotropin receptor. Mol Cell Endocrinol 127:81-90 (1997).
42. Brydon L, Roka F, Petit L, de Coppet P, Tissot M, Barrett P, et al. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol 13:2025-2038 (1999).
43. Offermanns S, Wieland T., Homann, D, Sandmann J, Bombien E, Spicher K, et al. Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11. Mol Pharmacol 45:890-898 (1994).
44. Santos-Alvarez J and Sanchez-Margalet V. G protein G alpha q/11 and G alphai1,2 are activated by pancreastatin receptors in rat liver: studies with GTP-gamma 35S and azido-GTP-alpha-32P. J Cell Biochem 73:469-477 (1999).
45. Laugwitz KL, Allgeier A, Offermanns S, Spicher K, Van Sande J, Dumont JE, et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci USA 93:116-120 (1996).
46. Cordeaux Y, Briddon SJ, Megson AE, McDonnell J, Dickenson JM and Hill SJ. Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. Mol Pharmacol 58:1075-1084 (2000).
47. Gudermann T, Schoneberg T and Schultz G. Functional and structural complexity of signal transduction via G-protein-coupled receptors. Annu Rev Neurosci 20:399-427 (1997).
48. Nasman J, Kukkonen JP, Ammoun S and Akerman KE. Role of G-protein availability in differential signaling by α2-adrenoceptors. Biochem Pharmacol 62:913-922 (2001).
49. Jin LQ, Wang HY and Friedman E. Stimulated D(1) dopamine receptors couple to multiple Gα proteins in different brain regions. J Neurochem 78:981-990 (2001).
50. Chakrabarti S, Prather PL, Yu L, Law PY and Loh HH. Expression of the mu-opioid receptor in CHO cells: ability of μ-opioid ligands to promote α-azidoanilido[32P]GTP labeling of multiple G protein alpha subunits. J Neurochem 64:2534-2543 (1995).
51. Takasu H, Gardella TJ, Luck MD, Potts JT Jr. and Bringhurst FR. Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: implications for design of signal-specific PTH ligands. Biochemistry 38:13453-13460 (1999).
52. Pommier B, Da Nascimento S, Dumont S, Bellier B, Million E, Garbay C, et al. The cholecystokinin B receptor is coupled to two effector pathways through pertussis toxin-sensitive and -insensitive G proteins. J Neurochem 73:281-288 (1999).
53. Sagan S, Chassaing G, Pradier L and Lavielle S. Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors. J Pharmacol Exp Ther 276:1039-1048 (1996).
54. Maudsley S, Davidson L, Pawson AJ, Chan R, de Maturana RL and Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 64:7533-7544 (2004).
55. Gong H, Sun H, Koch WJ, Rau T, Eschenhagen T, Ravens U, et al. Specific β(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the β(2)AR in myocytes from failing human heart. Circulation 105:2497-2503 (2002).
56. Yu Y, Zhang L, Yin X, Sun H, Uhl GR and Wang JB. μ opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 272:28869-28874 (1997).
57. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024 (1996).
58. Maudsley S, Gent JP, Findlay JB and Donnelly D. The relationship between the agonist-induced activation and desensitization of the human tachykinin NK2 receptor expressed in Xenopus oocytes. Br J Pharmacol 124:675-684 (1998).
59. Stout BD, Clarke WP and Berg KA. Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 302:957-962 (2002).
60. van Hooft JA and Vijverberg HP. Selection of distinct conformational states of the 5-HT3 receptor by full and partial agonists. Br J Pharmacol 117:839-846 (1996).
61. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 51:357-362 (1997).
62. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S and Struthers RS. Differential desensitization, receptor phosphorylation, β-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem 279:23214-23222 (2004).
63. May LT, Avlani VA, Sexton PM and Christopoulos A. Allosteric modulation of G protein-coupled receptors. Curr Pharm Des 10:2003-2013 (2004).
64. Hebert TE and Bouvier M. Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol. 76:1-11 (1998).
65. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, et al. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396:674-679 (1998).
66. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, et al. Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. J Biol Chem 275:26128-26135 (2000).
67. Franco R, Ferre S, Agnati L, Torvinen M, Gines S, Hillion J, et al. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 23:S50-59 (2000).
68. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, et al. A peptide derived from a β2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271:16384-16392 (1996).
69. Bai M, Trivedi S, Kifor O, Quinn SJ and Brown EM. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. Proc Natl Acad Sci USA 96:2834-2839 (1999).
70. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC and Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869 (2000).
71. Ciruela F, Escriche M, Burgueno J, Angulo E, Casado V, Soloviev MM, Canela EI, et al. Metabotropic glutamate 1α and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem 276:18345-18351 (2001).
72. Ferre S, Torvinen M, Antoniou K, Irenius E, Civelli O, Arenas E, et al. Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. J Biol Chem 273:4718-4724 (1998).
73. Jordan BA and Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700 (1999).
74. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339 (1998).
75. Evans BN, Rosenblatt MI, Mnayer LO, Oliver KR and Dickerson IM. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 275:31438-31443 (2000).
76. Kitamuro T, Takahashi K, Totsune K, Nakayama M, Murakami O, Hida W, et al. Differential expression of adrenomedullin and its receptor component, receptor activity modifying protein (RAMP) 2 during hypoxia in cultured human neuroblastoma cells. Peptides 11:1795-1801 (2001).
77. Sueur S, Pesant M, Rochette L and Connat JL. Antiapoptotic effect of calcitonin gene-related peptide on oxidative stress-induced injury in H9c2 cardiomyocytes via the RAMP1/CRLR complex. J Mol Cell Cardiol 39:955-963 (2005).
78. Tadokoro K, Nishikimi T, Mori Y, Wang X, Akimoto K. and Matsuoka H. Altered gene expression of adrenomedullin and its receptor system and molecular forms of tissue adrenomedullin in left ventricular hypertrophy induced by malignant hypertension. Regul Pept. 112:71-78 (2003).
79. Freedman NJ and Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res 51:319-351 (1996).
80. Stoffel RH 3rd, Pitcher JA and Lefkowitz RJ. Targeting G protein-coupled receptor kinases to their receptor substrates. J Membr Biol 157:1-8(1997).
81. Lawler OA, Miggin SM and Kinsella BT. Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-, to G(i)-, and to G(q)-coupled effector signaling. J Biol Chem 276:33596-33607 (2001).
82. Herrero I, Miras-Portugal MT and Sanchez-Prieto J. Functional switch from facilitation to inhibition in the control of glutamate release by metabotropic glutamate receptors. J Biol Chem 273:1951-1958 (1998).
83. Luttrell LM. Transmembrane signaling by G protein-coupled receptors. Meth Mol Biol In press (2005).
84. Pak Y, Pham N and Rotin D. Direct binding of the beta1 adrenergic receptor to the cyclic AMP-dependent guanine nucleotide exchange factor CNrasGEF leads to Ras activation. Mol Cell Biol 22:7942-7952 (2002).
85. Ali MS, Sayeski PP, Dirksen LB, Hayzer DJ, Marrero MB and Bernstein, KE. Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J Biol Chem 272:23382-23388 (1997).
86. Luttrell LM and Lefkowitz RJ. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465 (2002).
87. Perry SJ and Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol. 12:130-138 (2002).
88. Luttrell LM, Ferguson SSG, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F-T, et al. β-Arrestin-dependent formation of β2 adrenergic receptor/Src protein kinase complexes. Science 283:655-661 (1999).
89. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Dery O and Bunnett NW. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97: 11086-11091 (2000).
90. McDonald PH, Chow C-W, Miller WE, LaPorte SA, Field ME, Lin F-T, et al. β-Arrestin 2: A receptor-regulated MAPK scaffold for the activation of JNK3. Science 290:1574-1577 (2000).
91. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD and Bunnett NW. β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148: 1267-1281 (2000).
92. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, et al. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc Natl Acad Sci USA 98:2449-2454 (2001).
93. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, et al. Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science 298:834-836 (2002).
94. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM and Onorato JJ. Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 272:28849-28852 (1997).
95. Tohgo A, Pierce KL, Choy EW, Lefkowitz RJ and Luttrell LM. β-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 277:9429-9436 (2002).
96. Bunemann M and Hosey MM. G-protein coupled receptor kinases as modulators of G-protein signaling. J Physiol 517:5-23(1999).
97. Hayes JS and Brunton LL. Functional compartments in cyclic nucleotide action. J Cyclic Nucleotide Res 8:1-16 (1982).
98. Buxton IL and Brunton LL. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 258:10233-10239 (1983).
99. Harper JF, Haddox MK, Johanson RA, Hanley RM and Steiner AL. Compartmentation of second messenger action: immunocytochemical and biochemical evidence. Vitam Horm 42:197-252 (1985).
100. Graeser D and Neubig RR. Compartmentation of receptors and guanine nucleotide-binding proteins in NG108-15 cells: lack of cross-talk in agonist binding among the α2-adrenergic, muscarinic, and opiate receptors. Mol Pharmacol 43:434-443 (1993).
101. 2+ signaling complexes in pancreatic acini. J Biol Chem 271:24684-24690 (1996).
102. Steinberg SF and Brunton LL. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41:751-773 (2001).
103. Neubig RR. Membrane organization in G-protein mechanisms. FASEB J 8:939-946 (1994).
104. Ostrom RS, Post SR and Insel PA. Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving G(s). J Pharmacol Exp Ther 294:407-412 (2000).
105. Galbiati F, Razani B and Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell 106:403-411 (2001).
106. Rimoldi V, Reversi A, Taverna E, Rosa P, Francolini M, Cassoni P, et al. Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene 22:6054-6060 (2003).
107. Brady AE and Limbird LE. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal 14:297-309 (2002).
108. Hall RA and Lefkowitz RJ. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res 91:672-680 (2002).
109. Malbon CC, Tao J and Wang HY. AKAPs (A-kinase anchoring proteins) and molecules that compose their G-protein-coupled receptor signalling complexes. Biochem J 379:1-9 (2004).
110. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, et al. The β(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275:9572-9580 (2000).
111. 2+-dependent BK channel signaling complex by binding to β2 adrenergic receptor. EMBO J 23:2196-2205 (2004).
112. Bockaert J, Marin P, Dumuis A and Fagni L. The 'magic tail' of G protein-coupled receptors: An anchorage for functional protein networks. FEBS Lett. 546:65-72 (2003).
113. Hirbec H, Perestenko O, Nishimune A, Meyer G, Nakanishi S, Henley JM, et al. The PDZ proteins PICK1, GRIP and syntenin bind multiple glutamate receptor subtypes. Analysis of PDZ binding motifs. J Biol Chem 277: 15221-15224 (2002).
114. Sala C, Piech V, Wilson NR, Passafaro M, Liu G and Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 31: 115-130 (2001).
115. Mao L, Yang L, Tang Q, Samdani S, Zhang G and Wang JQ. The scaffold protein Homer 1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascade in neurons. J Neurosci 25: 2741-2752 (2005).
116. Salanova M, Priori G, Barone V, Intravaia E, Flucher B, Ciruela F, McIlhinney RA, Parys JB, et al. Homer protein and InsP(3) receptors co-localise in the longitudinal sarcoplasmic reticulum of skeletal muscle fibres. Cell Calcium 32: 193-200 (2002).
117. Westhoff JH, Hwang SY, Scott Duncan R, Ozawa F, Volpe P, Inokuchi K, et al. Vesl/homer proteins regulate ryanodine receptor type 2 function and intracellular calcium signaling. Cell Calcium 34: 261-269 (2003).
118. Fagni L, Worley PF and Ango F. Homer as both a scaffold and transduction molecule. Sci STKE 137:RE8 (2002)
119. Bermak JC, Li M, Bullock C and Zhou QY. Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein. Nat Cell Biol 3: 492-498 (2001).
120. Prezeau L, Richman JG, Edwards SW and Limbird LE. The zeta isoform of 14-3-3 proteins interact with the third intracellular loop of different alpha2-adrenergic receptor subtypes. J Biol Chem 274:13462-13469 (1999).
121. Couve A, Kittler JT, Uren JM, Calver AR, Pangalos MN, Walsh FS, et al. Association of GABA(B) receptors and members of the 14-3-3 family of signaling proteins. Mol Cell Neurosci 17: 317-328 (2001).
122. Hebert LE, Scherr PA, Bienias JL, Bennett DA and Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 60:1119-22 (2003).
123. Coyle JT, Price DL and DeLong MR. Alzheimer's disease: a disorder of cotical cholinergic innervation. Science 219:1184-1190 (1983).
124. Ladner CJ And Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57:719-731 (1998).
125. Waller SB, Bal MJ, Reynolds MA and London ED. Muscarinic binding and choline acetyltransferase in postmortem brains of demented patients. Can. J. Neurol. Sci. 13:528-532 (1986).
126. Cohen RM, Podruchny TA, Bokde ALW, Carson RE, Herscovitvh P, Keisewetter DO, et al. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-4 allele. Synapse 49:150-156 (2003).
127. Hellstrom-Lindahl E. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 393: 255-263 (2000).
128. Zuchner T, Schliebs R and Perez-Polo JR. Down-regulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer's disease-relevant genes and proteins. J Neurochem. 95, 20-32 (2005).
129. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A and Inestrosa NC. M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis 17: 337-348 (2004).
130. Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28: 1168-1175 (2003).
131. Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M, et al. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol Rev 54: 247-264 (2002).
132. Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, et al. SGS742: the first GABAB receptor in clinical trials. Biochem Pharmacol 68:1479-1487 (2004)..
133. Shiozaki K and Iseki E. Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy Bodies and Alzheimer's disease. J Neurol Sci 223:145-148 (2004).
134. Muma NA, Mariyappa R, Williams K and Lee JM. Differences in regional and subcellular localization of Gq/11 and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters. Synapse 47:58-65 (2003)
135. Popescu BO, Cedazo-Minguez A, Benedikz E, Nishimura T, Winblad B, Ankarcrona M, et al. γ-secretase activity of presenilin 1 regulates acetylcholine muscarinic receptor-mediated signal transduction J Biol Chem 279:6455-6464 (2004).
136. Suo Z, Wu M, Citron BA, Wong GT and Festoff BW. Abnormality of G protein coupled receptor kinase at prodromal and early stages of Alzheimer's disease: An association with early β-amyloid accumulation. J Neurosci 24:3444-3452 (2004).
137. Suo Z, Wu M, Citron BA, Palazzo RE and Festoff BW. Rapid tau aggregation and delayed hippocampal neuronal death by persistent thrombin signaling. J Biol Chem 278:37681-37689 (2003).
138. Donovan FM and Cunningham DD. Signaling pathways involved in thrombin-induced cell protection. J Biol Chem 273:12746-12752 (1998).
139. Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, et al. Serotonergic polymorphisms (5HTLPR and 5HT2A): association studies with psychosis in Alzheimers disease. Genet Test 7:309-314 (2003).
140. Feuerstein TJ, Gleichauf O and Landwehrmeyer GB. Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons. Naunyn Schmeidebergs Arch. Pharmacol. 354:618-626 (1996).
141. Garcia-Alloza M, Hirst WD, Chen CP, Lasheras B, Francis PT and Ramirez MJ. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 29: 410-416 (2004).
142. Perez-Garcia GS and Meneses A. Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behav Brain Res 163: 136-140 (2005).
143. Maillet M, Robert SJ and Lezoualc'h F. New insights into serotonin 5-HT4 receptors : a novel therapeutic target for Alzheimer's disease? Curr Alzheimer Res 1: 97-85 (2004).
144. Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, et al. Lecozotan (SRA-333): A selective serotonin 1 A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther. 314:1274-1289 (2005).
145. Dewar D, Chalmers DT, Graham DI and McCulloch J. Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus, Brain Res. 553: 58-64 (1991).
146. Vincent AM, Mohammad Y, Ahmad I, Greenberg R and Maiese K. Metabotropic glutamate receptors prevent nitric oxide induced programmed cell death, J. Neurosci. Res. 50: 549-564 (1997).
147. Lee RK, Jimenez J, Cox AJ and Wurtman RJ. Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. Ann N Y Acad Sci 777: 338-343 (1996).
148. Furukawa K, Barger SW, Blalock EM and Mattson MP. Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid precursor protein. Nature 379: 74-78 (1996).
149. Taylor DL, Diemel LT and Pocock JM. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 23: 2150-2160 (2003).
150. Riedel G, Opitz T and Reymann KG. Blockade of metabotropic glutamate receptors protects hippocampal neurons from hypoxia-induced cell death in rat in vivo, Prog. Neuro-psychopharmacol. Biol. Psychiatry 20: 1253-1263 (1996).
151. Moldrich RX and Beart PM. Emerging signaling and protein interactions mediated via metabotropic glutamate receptors. Curr Drug Targets CNS Neurol Disord 2:109-122 (2003).
152. Higgins GA, Ballard TM, Kew JNC, Grayson-Richards J, Kemp JA, Adam G, et al. Pharmacological manipulation of mGLu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46:907-917 (2004).
153. May LT, Avlan VA, Sexton PA and Christopoulos A. Allosteric modulation of G protein-coupled receptors. Curr. Pharm. Design 10:2003-2013 (2004).
154. Blake AD, Bot G, Freeman JC and Reisine T. Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem 272:782-790 (1997).
155. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, et al. HIV coreceptor downregulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 186: 139-146 (1997).
156. Signoret N, Oldridge J, Pelchen-Matthews A, Klase PJ, Tran T, Brass LF, et al. Phorbol esters and SDF-1 induce rapid endocytosis and down-regulation of the chemokine receptor CXCR4. J Cell Biol 139:651-664 (1997).
157. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279 (1997).
158. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187:1215-1224 (1998).
159. Domingo E, Menendez-Arias L, Quinones-Mateu ME, Holguin A, Gutierrez-Rivas M, Martinez MA, et al. Viral quasispecies and the problem
160. Harrigan PR, Bloor S and Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 72:3773-3778 (1998).
161. Schols D, Este JA, Cabrera C and De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 72:4032-4037 (1998).
162. Rodriguez-Frade JM, Vila-Coro AJ, Martin A, Nieto M, Sanchez-Madrid F, Proudfoot AE, et al. Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis. J Cell Biol 144:755-765 (1999).
163. Kuhmann SE, Platt EJ, Kozak SL and Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 74:7005-7015 (2000).
164. Mukhopadhyay S, McIntosh HH, Houston DB and Howlett AC. The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol Pharmacol 57:162-170 (2000).
165. Romano C, Yang WL and O'Malley KL. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 271:28612-28616 (1996).
166. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, et al. Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396:679-682 (1998).
167. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C and Franco R. Ligand-induced phosphorylation, clustering, and desensitization of A1 adenosine receptors. Mol Pharmacol 52:788-797 (1997).
168. Cvejic S and Devi LA. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem 272:26959-26964 (1997).
169. Bai M, Trivedi S and Brown EM. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J Biol Chem 273:23605-23610 (1998).
170. Kenakin TP. Agonist selective receptor states: the new level of selectivity? Pharmacology News 5:20-25 (1998).
171. Lefkowitz RJ, Pierce KL and Luttrell LM. Dancing with different partners: protein kinase a phosphorylation of seven membrane-spanning receptors regulates their G protein-coupling specificity. Mol Pharmacol 62:971-974 (2002).
172. El-Bakri NK, Adem A, Suliman IA, Mulugeta E, Karlsson E, Lindgren JU, et al. Estrogen and progesterone treatment: effects on muscarinic M(4) receptor subtype in the rat brain. Brain Res. 6:131-137 (2002)..
173. Mulutega E, Karlsson E, Islam A, Kalaria R, Mangat H, Winblad B, et al. Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 960:259-262 (2003).
174. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 22:541-546 (2001).
175. Kalaria RN and Andorn AC. Adrenergic receptors in aging and Alzheimer's disease: decreased alpha 2-receptors demonstrated by [3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol Aging 12:131-136 (1991).
176. Kemppainen N, Laine M, Laakso MP, Kaasinen V, Nagren K, Vahlberg T, et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 18:149-154 (2003).
177. Jansen KL, Faull RL, Dragunow M, Synek BL. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors - an autoradiographic study. Neuroscience 39:613-627 (1990).
178. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 134:525-538 (2005).
179. Chu DC, Penney JB Jr and Young AB. Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer's disease. Neurosci Lett 82: 246-252 (1987).
180. Barreda-Gomez G, Giralt MT and Rodriguez-Puertas R. Effects of central galanin administration on muscarinic cholinergic and galanin receptor G protein coupling. Neuropeptides 39:157-160 (2005).
181. Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J. Comp. Neurol. 273:543-557 (1988).
182. Silva, AP, Xapelli S, Grouzmann E and Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 4:331-347 (2005).
183. Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 38:10-16 (2004).
184. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M and de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904-1913 (2005).
185. Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, et al. Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99:721-729 (2000).
186. Kohzuki M, Onodera H, Yasujima M, Itoyama Y, Kanazawa M, Sato T, et al. Endothelin receptors in ischemic rat brain and Alzheimer brain. J. Cardiovasc. Pharmacol. 26:329-331 (1995).
187. Bajetto A, Bonavia R, Barbero S, Florio T and Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol. 22:147-184 (2001).